9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Condition Cancer Estimated Enrollment: 241 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Study ID Numbers: CDR0000573913|NCI-08-C-N013|P07268 Study First Received: May 16, 2009 Last Updated: February 16, 2012 Estimated Primary Completion Date: October 2007 Primary Outcome Measures: Analyses of stored human samples, specimens, and data collected from patients previously enrolled in a terminated National Cancer Institute-Institutional Review Board clinical trial|Correlation of plasma levels and pharmacokinetics with disease burden and presence of antibodies|Correlation of tumor markers with disease burden|Utility of tumor markers for following patients after treatment Sponsors and Collaborators: National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Result Received: No Study Results Posted Website...

Continue reading

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Condition Cancer Estimated Enrollment: 130 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment Study ID Numbers: INS-05-001|CDR0000581128 Study First Received: October 1, 2007 Last Updated: January 14, 2014 Estimated Primary Completion Date: February 2010 Primary Outcome Measures: Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)|Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing|Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing|Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing Sponsors and Collaborators: INSYS Therapeutics...

Continue reading

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Condition Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Primary Hepatocellular Carcinoma|Adult Subependymoma|Advanced Adult Primary Liver Cancer|Advanced Malignant Mesothelioma|Male Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Malignant Mesothelioma|Recurrent Metastatic Squamous Neck Cancer...

Continue reading

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Condition Ovarian|Melanoma|Renal|Prostate|Colorectal|Endometrial Carcinoma|Cervical Carcinoma|Testicular Cancer|Thyroid Cancer|Small Cell Lung Carcinoma|Mesothelioma|Breast Carcinoma|Esophageal Carcinoma|Gastric Cancer|Pancreatic Carcinoma|Neuroendocrine Cancer|Liver Cancer|Gallbladder Cancer|Biliary Tract Cancer|Anal Carcinoma|Bone Sarcomas|Soft Tissue Sarcomas|Carcinoma of Unknown Origin, Primary Estimated Enrollment: 12 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MKC1106-PP-001 Study First Received: January 12, 2007 Last Updated: August 2, 2010 Estimated Primary Completion Date: September 2009 Primary Outcome Measures: To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP|to determine the blood plasmid levels by PCR analysis|measure cytokine...

Continue reading

B-Receptor Signaling in Cardiomyopathy

Condition Carcinomas|Amyloidosis|Anal Cancer|Anemia|Cholangiocarcinoma of the Extrahepatic Bile Duct|Transitional Cell Carcinoma of Bladder|Bone Marrow Transplant Failure|Bone Cancer|Cancer of Brain and Nervous System|Breast Cancer|Carcinoma of the Large Intestine|Endocrine Cancer|Esophageal Cancer|Eye Cancer|Gall Bladder Cancer|Gastric (Stomach) Cancer|Gastrooesophageal Cancer|Gastrointestinal Stromal Tumor (GIST)|Gynecologic Cancers|Head and Neck Cancers|Hepatobiliary Neoplasm|Kidney (Renal Cell) Cancer|Leukemia|Lung Cancer|Hodgkin Disease|Lymphoma, Non-Hodgkin|Mesothelioma|Multiple Myeloma|Myelodysplastic Syndromes (MDS)|Neuroendocrine Tumors|Myeloproliferative Disorders|Pancreatic Cancer|Prostate Cancer|Skin Cancer|Soft Tissue Sarcoma|Testicular Cancer|Thymus Cancer|Thyroid Cancer Estimated Enrollment: 99 Age Group: up to 40 Years   (Child, Adult) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: PEDSVAR0038|SU-11172008-1345 Study First Received: June 1, 2010 Last Updated: November 16, 2015 Estimated Primary Completion Date: October 2010 Primary Outcome Measures: Development of...

Continue reading

Collecting Tumor Samples From Patients With Gynecological Tumors

Condition Borderline Ovarian Clear Cell Tumor|Borderline Ovarian Serous Tumor|Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Childhood Embryonal Rhabdomyosarcoma|Childhood Malignant Ovarian Germ Cell Tumor|Endometrioid Stromal Sarcoma|Gestational Trophoblastic Tumor|Malignant Mesothelioma|Malignant Ovarian Epithelial Tumor|Melanoma|Neoplasm of Uncertain Malignant Potential|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Paget Disease of the Vulva|Recurrent Cervical Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Recurrent Vaginal Carcinoma|Recurrent Vulvar Carcinoma|Stage I Ovarian Cancer|Stage I Uterine Corpus Cancer|Stage I Vaginal Cancer|Stage I Vulvar Cancer|Stage IA Cervical Cancer|Stage IA Fallopian Tube Cancer|Stage IA Ovarian Cancer|Stage IA Ovarian Germ Cell Tumor|Stage IB...

Continue reading

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Condition Anal Cancer|Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Pancreatic Cancer Estimated Enrollment: 29 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: ID97-027|P30CA016672|MDA-ID-97027|NCI-T97-0034|CDR0000065681 Study First Received: November 1, 1999 Last Updated: July 27, 2012 Estimated Primary Completion Date: October 2001 Primary Outcome Measures: Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12 Sponsors and Collaborators: M.D. Anderson Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00003046...

Continue reading

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

Condition Peritoneal Neoplasms|Retroperitoneal Neoplasms|Gastrointestinal Neoplasms|Adenocarcinoma|Neuroblastoma|Ovarian Neoplasms|Sarcoma|Adrenocortical Carcinoma|Wilms Tumor|Rhabdomyosarcoma|Desmoplastic Small Round Cell Tumor Estimated Enrollment: 10 Age Group: 3 Years to 18 Years   (Child, Adult) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2005-0917 Study First Received: February 15, 2007 Last Updated: March 29, 2012 Estimated Primary Completion Date: April 2011 Primary Outcome Measures: Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal cancer Sponsors and Collaborators: M.D. Anderson Cancer Center Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00436657...

Continue reading

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

Condition Non Small Cell Lung Carcinoma Estimated Enrollment: 228 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: H3E-BL-O027-PS2|H3E - US -I023|INCA-Lung001 Study First Received: December 30, 2010 Last Updated: April 18, 2013 Estimated Primary Completion Date: January 2012 Primary Outcome Measures: Overall survival|Safety evaluation|Progression free survival|Response Rate Sponsors and Collaborators: Instituto Nacional de Cancer, Brazil|Eli Lilly and Company Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01836575...

Continue reading

A Study in Non Small Cell Lung Cancer

Condition Non Small Cell Lung Cancer Estimated Enrollment: 63 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 13797|I2I-MC-JMMG Study First Received: June 1, 2010 Last Updated: September 5, 2014 Estimated Primary Completion Date: May 2013 Primary Outcome Measures: Phase 2: Progression Free Survival Time|Phase 1: Recommended Phase 2 Dose of LY2603618|Phase 2: Overall Survival|Phase 2: Overall Tumor Response Rate: Percentage of Participants who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR)|Phase 2: Change in Tumor Size|Phase 1: Pharmacokinetic: Maximum Concentration (Cmax) (Pemetrexed, Cisplatin and LY2603618)|Phase 1:...

Continue reading